<li>carbamazepine<p>carbamazepine will decrease the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>crofelemer<p>crofelemer increases levels of montelukast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>deferasirox<p>deferasirox will decrease the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of montelukast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.<span><br><br></span>elvitegravir/cobicistat/emtricitabine/tenofovir df decreases levels of montelukast by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Elvitegravir is a moderate CYP2C9 inducer.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>iloperidone<p>iloperidone increases levels of montelukast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, montelukast. affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C9 substrates. .<span><br><br></span>lumacaftor/ivacaftor decreases levels of montelukast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dose adjustment for montelukast is recommended.</p></li><li>mitotane<p>mitotane decreases levels of montelukast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>nefazodone<p>nefazodone will increase the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nitisinone<p>nitisinone will increase the level or effect of montelukast by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b decreases levels of montelukast by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. .</p></li><li>rifabutin<p>rifabutin will decrease the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin will decrease the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li>